The 35th European Society for Medical Oncology (ESMO) Congress begins this Friday in Milan, Italy. It's a big deal for oncologists with the presentation of vital research advances. Myrexis is not present at the meeting and that may be the cause of the current downturn - no news!
"Myrexis is not present at the meeting and that may be the cause of the current downturn - no news!"
Presents an interesting possibility--management may very well be negotiating with FDA to shortcut approval of Azixa. Results of trials against GBM have been impressive enough to give some hope for that; results against melanoma in salvage situations have been good enough not to undercut the attempt. While bargaining with FDA, smart management keeps a low public profile.
If smart management does that, then I wonder what MYRX management will do. Smart management doesn't have their company shares trading half of cash. Smart management cares about the shareholders. Smart management doesn't use the company as a personal piggy bank. Smart management doesn't think a public company is really a non-profit. Smart management doesn't stack the board with lackeys who know nothing about earnings. Since this is not smart management, I think the next move will be a new corporate jet.